
KMTS Stock Forecast & Price Target
KMTS Analyst Ratings
Bulls say
Kestra Medical Techs is a commercial-stage MedTech company with a promising product, the ASSURE Cardiac Recovery System, which has received FDA approval and is gaining market share in the rapidly growing WCD market. The company's expanding salesforce, positive real-world data, and strategic collaborations position it well for further revenue acceleration and gross margin expansion. Risks to our Buy rating and $32 price target include commercial execution, regulatory and reimbursement decisions, efforts to improve profitability, competition, and balance sheet.
Bears say
Kestra Medical Techs is a relatively new company that has received FDA approval for its ASSURE Cardiac Recovery System. However, its stock should be approached with caution due to its limited financial history and the potential for market competition. It is also worth noting that while the company's revenue and margin have been steadily increasing, it may take a while for new sales representatives to reach full productivity and for the company to drive further improvements in its conversion rate.
This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares